About Frontier Bio
Frontier Bio helps surgeons replace damaged blood vessels and gives researchers lab-grown tissue for experiments. Its living vascular graft uses a patient's own cells and can be implanted during one operation. The company also develops tissue platforms for research on regenerative medicine, personalized medicine, and disease modeling. It works with academic, pharmaceutical, and industrial researchers. Frontier Bio aims to use these programs as a foundation for organ-scale engineered tissue.
Frontier Bio is based in Hayward, California. Eric Bennett is chief executive officer. He previously served as chief technology officer at Aether, where he developed low-cost bioprinters. Bennett's background includes brain-computer interfaces, microfluidics, and tissue engineering. Sam Pashneh-Tala is chief technology officer. His prior research focused on tissue-engineered blood vessels for clinical and laboratory use. He previously ran a consultancy for tissue engineering and medical-device design.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 27, 2026 | Nov 10, 2026 | $380,000of $1.0M target | 6 | $63,333 | Simple Agreement for Future Equity (SAFE), convertible into preferred stockRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Frontier Bio
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Aug 29, 2025 | Investment | Undisclosed | Immortal Dragons | Frontier Bio news listing ↗ |
Why Investors Backed Frontier Bio
Frontier Bio develops living vascular grafts and lab-grown tissue platforms. Frontier Bio's case is that a graft can regenerate instead of remaining synthetic. The broader plan is to use vascular engineering as the foundation for organ-scale tissues.
The problem it targets
Surgeons now choose between synthetic grafts and the patient's own vein. Synthetic grafts carry a high clotting risk. Using a patient's vein adds hours and creates another wound. Traditional grafts also fail to form a living lining and clot quickly in comparable studies. Frontier Bio estimates that a successful alternative could help about 750,000 U.S. patients each year.
What the product does
The surgeon collects cells from a small fat sample and places them on Frontier Bio's scaffold. The graft is implanted during the same operation, and the surgeon attaches it like a conventional graft. As the scaffold dissolves, those cells build replacement tissue. The intended result is a living vessel rather than a traditional synthetic graft. The process combines seeding, implantation, and regeneration.
Progress so far
In its first large-animal study, Frontier Bio's graft formed a living lining within 14 days. The study reported no clotting or adverse effects. The work received Best Paper at VESS 2026. Frontier Bio also won Phase 1 of the NIH Complement-ARIE NAMs Challenge.
Who backs it
Immortal Dragons has backed Frontier Bio. Other investors include founders, chief executives, and senior leaders at $100 billion-plus companies. A Nobel laureate is also among its investors.
We wrote this summary from public statements by Frontier Bio and its investors. It is not investment advice.
Frontier Bio in the News
Leadership Team
Executive officers and directors listed on Frontier Bio's Form D filed Nov 10, 2026.
